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Neurobiology of Disease
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The loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and consequent depletion of striatal dopamine are known
to underlie the motor deficits observed in Parkinson’s disease (PD). Adaptive changes in dopaminergic terminals and in postsynaptic
striatal neurons can compensate for significant losses of striatal dopamine, resulting in preservation of motor behavior. In addition,
compensatory changes independent of striatal dopamine have been proposed based on PD therapies that modulate nondopaminergic
circuits within the basal ganglia. We used a genetic strategy to selectively destroy dopaminergic neurons inmice during development to
determine the necessity of these neurons for themaintenance of normalmotor behavior in adult and agedmice.We find that loss of 90%
of SNc dopaminergic neurons and consequent depletion of95% of striatal dopamine does not result in changes in motor behavior in
young-adult or agedmice as evaluated by an extensive array ofmotor behavior tests. Treatment of agedmutantmice with the dopamine
receptor antagonist haloperidol precipitated motor behavior deficits in aged mutant mice, indicating that5% of striatal dopamine is
sufficient to maintain motor function in these mice. We also found that mutant mice exhibit an exaggerated response to L-DOPA
compared with control mice, suggesting that preservation of motor function involves sensitization of striatal dopamine receptors. Our
results indicate that congenital loss of dopaminergic neurons induces remarkable adaptions in the nigrostriatal system where limited
amounts of dopamine in the dorsal striatum can maintain normal motor function.
Introduction
Parkinson’s disease (PD) is themost commonneurodegenerative
movement disorder, affecting 1% of the population60 years of
age. Progressive degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNc) and resultant depletion of
dopamine from the striatumunderlie themotor behavior deficits
observed in PD patients and in animals that have sustained dam-
age to the nigrostriatal pathway (Dauer and Przedborski, 2003).
Although the central role of midbrain dopaminergic neurons in
the pathogenesis of PD is well established, efforts to rescue de-
generating SNc dopaminergic neurons in PD patients have been
unsuccessful. Alternative strategies that bypass dopaminergic
neuron function by altering activity of basal ganglia circuits in-
dependently of dopamine, such as deep-brain stimulation of the
subthalamic nucleus or globus palidus (Ponce and Lozano, 2010)
or antagonism of A2 adenosine receptors (Hickey and Stacy,
2012), have shown efficacy in relieving the motor symptoms of
PD. These findings suggest that basal ganglia function can be
restored independently of SNc dopaminergic neurons.
Motor behavior changes resulting from damage to dopami-
nergic neurons during development are of interest for several
reasons. First, 6-hydroxydopamine (6-OHDA) administered to
neonatal rats results in near complete depletion of striatal
dopamine but produces less severe deficits in motor behavior
compared with adult animals sustaining damage of the same
magnitude (Breese et al., 2005). The mechanism underlying this
behavior sparing is reportedly independent of dopamine (Bruno
et al., 1985; Duncan et al., 1987). Thus, animal models in which
dopamine is severely depleted during development provide an
opportunity to study potential nondopaminergic mechanisms of
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plasticity in developing dopaminergic circuits. Animal models in
which developmental damage to dopaminergic neurons is mod-
erate are also of significant interest. Partial damage to the nigro-
striatal pathway resulting from prenatal or early postnatal
exposure to toxins renders mice more vulnerable to dopaminer-
gic neuron damage later in life and has been proposed to predis-
pose humans to PD (Carvey et al., 2003; Bakos et al., 2004; Barlow
et al., 2007; Muthian et al., 2010). These studies have provided
important insights into the effects of developmental damage of
dopaminergic neurons on motor behavior and on increased vul-
nerability of dopaminergic neurons to a second toxin treatment
in adulthood. However, the use of exogenous toxins to destroy
dopaminergic neurons during development is limited by a num-
ber of factors, including uncertain specificity of the toxins and
dosing limitations necessitated by the potential for systemic tox-
icity to pregnant animals. Models that avoid these confounds
have the potential to provide new insights into the consequences
of developmental dopaminergic neuron damage and into the
mechanisms underlying plasticity in the developing nigrostriatal
system.
Here we expressed diphtheria toxin in dopaminergic neurons
to create a model of developmental damage that is specific for
dopaminergic neurons. A broad spectrum of motor behavior
tests demonstrated that, surprisingly, near complete loss of stri-
atal dopamine produced no detectablemotor behavior deficits in
adult or aged mutant mice. Transient blockade of dopaminergic
transmission using haloperidol precipitated motor dysfunction
in mutant mice indistinguishable from that seen in control mice,
indicating that the small amount of residual dopamine present in
the striatum of these mice is sufficient tomaintain normal motor
function. In addition, mutant mice show increased locomotor be-
havior in response toL-DOPAatadose thatdoesnotalter locomotor
activity in control mice, suggesting that the mechanism by which
motor behavior is preserved in DAT-DTA (Dopamine transporterCre-
RosafloxSTOPfloxdta) mice involves functional sensitization of striatal do-
pamine receptors.
Materials andMethods
Animal generation. Institutionally approved protocols were followed for
all animal studies. To generate mice with conditional expression of at-
tenuated diphtheria toxin (DTA) in dopaminergic neurons, mice ex-
pressing DTA from the Rosa locus (RosafloxSTOPfloxdta/) (Wu et al.,
2006) were crossed with heterozygous mice expressing Cre from the
dopamine transporter (DAT) locus (DATCre/; Zhuang et al., 2005; Fig.
1A). These experimental mice are hereafter referred to as DAT-DTA
mice (RosafloxSTOPfloxdta/:DATCre/). Controlmice used in this study are
littermates or age-matched mice that have one DTA allele but no Cre
allele (RosafloxSTOPfloxdta/:DAT/). Previous studies have found no dif-
ference in locomotor activity in DAT/ and wild-type mice (Giros et
al., 1996).
Behavior testing. Behavior testing was performed using male and fe-
male mice from 1.5 to 24 months of age. The experimenter was blind to
the genotypes of the mice and to drug treatment during data acquisition.
Gross motor function (Rotarod). An accelerating Rotarod (Ugo Basile)
was used to evaluate motor coordination and balance. Five consecutive
acceleration trials were performed with a 5 min interval between trials as
described previously (Montana et al., 2009).
Sensorimotor battery. Tests in the sensorimotor battery were used as
previously described to evaluate balance, strength, coordination, and
skilled forelimb use (Jain et al., 2006; Meredith and Kang, 2006). In
addition, we evaluated movement initiation by measuring the time it
took a mouse to exit an 18  18 cm square (all four paws outside the
square) marked on a flat horizontal surface.
Locomotor activity (open field). Locomotor activity wasmeasured in an
open field using a VersaMax Animal Activity Monitoring System (Ac-
cuScan Instruments). Mice were habituated to the test room in their
cages for 1 h before testing. Locomotor activity was assessed by recording
photo beam breaks in a 42 (length)  42 (width)  30 (height) cm
chamber for 60 min. Total distance traveled, time spent moving, and the
number of beam breaks (horizontal activity) were calculated for the en-
tire chamber.
Gait analysis. Mice were trained to walk down a narrow walkway (1
m 6.5 cm) leading to a dark box. Following training, the walkway was
covered with plain white paper and ink was applied to the hindpaws by
pressing the mouse’s foot onto an ink pad. Toe spread (TS), intertoe
spread (ITS), stride width (SW), and stride length (SL) weremeasured as
previously described (Taylor et al., 2001). For eachmouse, aminimumof
two footprints (TS and ITS) or two sets of prints (SW and SL) were
measured for each parameter.
Haloperidol treatment. Twelve-month-old control mice and DAT-
DTA mice were given a single intraperitoneal injection of haloperidol
(Sigma-Aldrich) dissolved in DMSO at a dose of 1 mg/kg. Ten minutes
after administration of haloperidol, movement initiation was evaluated
as described above. Catalepsy was evaluated by measuring the time re-
quired for themouse to step down after its front or hindpawswere placed
on a 3 cm block (Weihmuller and Bruno, 1989; Mohajjel Nayebi, 2010).
Following these two tests (15 min after haloperidol administration),
micewere tested in the open field (as above). Following themeasurement
of open-field activity (80 min after haloperidol administration) move-
ment initiation and catalepsy were again evaluated.
Assessment of possible hypersensitivity to dopamine. Six-to-seven-
month-old control and DAT-DTA mice were given a single intraperito-
neal injection of L-DOPA (25 mg/kg) and carbidopa (10 mg/kg; both
drugs obtained from Sigma-Aldrich) dissolved in PBS containing 0.25%
ascorbic acid. Ten minutes after administration of L-DOPA, movement
initiation was evaluated as described above. Following this test (15min
after L-DOPA administration) mice were tested in the open field (as
above). After the measurement of open-field activity (80 min after
L-DOPA administration) movement initiation was again evaluated.
Quantitative real-time PCR.RNAwas purified fromdorsal striatum from
12-month-old DAT-DTA (N 9) and control (N 7) mice. RNA (1 g)
was reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen).
Quantitative real-time PCR (qRT-PCR) was performed using Fast SYBR
Green Master Mix (Applied Biosystems) and reactions were run in an Ap-
plied Biosystems 7900HTReal Time Thermal Cycler. All reactions were run
in triplicate and relative fold changes in RNAamountwere calculated by the
CTmethodusingGAPDHtonormalize samples (Livak and Schmittgen,
2001). qRT-PCR primers were designed by Primer Express software
(Applied Biosystems). Primer sequences are as follows (5	33	): D1:
forward-GCCATTCTGCATTGATTCCA, reverse-ATTCGCCCAGC-
CAAACC; D2: forward-CGTTATCATGAAGTCTAATGGGAGTTT,
reverse-GGCGGGCAGCATCCA.
Immunohistochemistry. At the conclusion of behavior analysis, mice
were deeply anesthetized and perfused through the heart with PBS
followed by 4% paraformaldehyde in PBS. Brains were removed imme-
diately after perfusion, postfixed overnight in paraformaldehyde, cryo-
protected with 30% sucrose, and rapidly frozen on dry ice. Brains from
postnatal day 0 (P0) mice were sectioned in the coronal plane at 20 m
andwere collected in series on slides. For 1.5–12-month-oldmice, 40m
coronal brain sections were collected in PBS. Free-floating (1.5–12-
month-old mice) coronal sections or slides with coronal sections (P0
mice) ofmidbrain and striatumwere labeledwith an antibody to tyrosine
hydroxylase (TH; Millipore Bioscience Research Reagents) as previously
described (Jain et al., 2006). TH-labeled neurons in the SNc and the
ventral tegmental area (VTA) were counted in every fourth section by an
investigator blinded to genotype. Profiles identified as neurons were TH-
positive profiles that contained a nucleus and at least one process. The
total number of neurons was determined by multiplying the number of
neurons counted by four. The entire SNc and VTA were included. For
SNc counts, all sections from Plate 52-63 (Franklin and Paxinos, 1997)
were included. For VTA counts, all sections from Plate 55-63 were in-
cluded. The border between the SNc and VTA was determined in each
section according to the borders outlined for these structures in the
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Franklin and Paxinos Brain Atlas (Franklin and Paxinos, 1997). TH-
positive neurons were also counted in all of the nuclei of the hypothala-
mus, in the dorsal thalamus, and in the periaqueductal gray of the same
5-month-old control andDAT-DTAmice used for SNc andVTA counts.
Neurons were identified as described above and were counted in every
fourth section (40 m). The total neuron number for each nucleus was
obtained by multiplying the neuron count for each nucleus by four.
Individual hypothalamic nuclei were identified based on borders out-
lined for these structures in the Franklin and Paxinos Brain Atlas. Sec-
tions corresponding to Plate 27-54 were included in these counts
(Franklin and Paxinos, 1997).
Using an unbiased stereological method for determining the areal
fraction occupied by an object (in this case TH-positive fibers) as previ-
ously described (Gundersen et al., 1988; Jain et al., 2006), TH-positive
fibers were quantified in the dorsal and ventral striatum of 5-month-old
DAT-DTA and control mice. For fiber counts in the dorsal striatum,
three 40 m coronal sections, corresponding to Plates 23, 26, and 29
(Franklin and Paxinos, 1997) were sampled. Two images from each sec-
tion were used in the analysis for a total of six images per brain. For the
ventral striatum, three 40 m coronal sections corresponding to Plates
21, 23, and 26were sampled using two images per section for a total of six
images per brain. The sections of striatum used for this analysis were
Figure 1. Dramatic loss of SNc and VTA neurons in DAT-DTA mice. A, Schematic illustrating breeding strategy to produce DAT-DTA mice. B, C, Weight of male and female DAT-DTA and control
mice. Female DAT-DTAmice weigh significantly less than control mice at 3–5 and 10–21months. Male DAT-DTAmice weigh significantly less than control mice at 10–21months (mean
 SEM,
Student’s t test, control vs DAT-DTA at each time point; *p 0.05, **p 0.01, ***p 0.001).D, Loss of TH-positive neurons in the ventral midbrain of DAT-DTAmice. The number of TH-positive
neurons is significantly decreased in the SNc and VTA of DAT-DTAmice compared with control mice at all ages studied (mean
 SEM, Student’s t test, control vs DAT-DTA at each time point; *p
0.05, **p 0.01, ***p 0.001). P0, N 3 of each genotype; 1.5 months, N 2 of each genotype; 5 months, N 4 of each genotype; 12 months, N 3 of each genotype. E, F, Nissl-labeled
coronal brain sections from 5-month-old mice showing large neurons in the SNc of control mice (E, arrows). These large neurons are absent in the SNc of DAT-DTA mice (F, arrows).
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obtained from the same brains that provided midbrain sections for
5-month-old SNc and VTA neuron counts.
Evaluation of dopaminergic neurons in the gut was performed on
whole-mount peeled sections of the submucosa from terminal ileum
using TH immunohistochemistry as previously described (Li et al.,
2004). Briefly, intestines were harvested from mice perfused with 4%
paraformaldehyde, fixed flat overnight, rinsed with PBS, peeled, and
prepared for TH immunohistochemistry using diaminobenzidine for
visualization.
Microscopy. All images were captured using an upright microscope
equipped for epifluorescence microscopy (Nikon 80i; CoolSnapES cam-
era). Images were processed using MetaMorph or Adobe Photoshop
software using global adjustments in brightness and contrast.
Biochemistry. Levels of dopamine and its metabolites homovanillic
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were deter-
mined in samples of dorsal striatum using HPLC with electrochemical
detection as previously described (Pehek et al., 1992).Mice were killed by
cervical dislocation. The brain was rapidly removed, frozen on dry ice,
and cut into 1 mm slices using a precooled mouse brain matrix (Stoelt-
ing). The dorsal striatumwas dissected from slices corresponding to Plate
23–31 in the Franklin and Paxinos Mouse Brain Atlas (Franklin and
Paxinos, 1997).
Statistical analysis.Data are reported as the mean
 SEM. Statistically
significant differences between multiple groups were determined using
two-way ANOVA and Bonferroni post-test. Comparisons between two
groups were determined using the Student’s t test.
Results
At all ages examined, DAT-DTA mice appear healthy and are
indistinguishable from littermate control mice. DAT-DTA mice
were weaned successfully with littermates and did not exhibit any
gross deficits in drinking or feeding behavior. However, at 3–5
months of age, female DAT-DTA mice weighed on average 10%
less than female control mice and at 10–21 months of age both
male and female DAT-DTA mice weighed 20% less than age-
matched and sex-matched control mice (Fig. 1B,C). DAT-DTA
mice survived to 24 months (at which time they were killed),
similar to control mice.
Expression of DTA from the DAT locus results in rapid,
progressive loss of dopaminergic neurons in the SNc and VTA
Loss of TH-positive neurons in the SNc was readily apparent by
P0 inDAT-DTAmice (Figs. 1D, 2A–D). Nissl staining of sections
adjacent to those used for TH labeling show that the loss of TH-
positive neurons is due to cell loss in the SNc and VTA and not to
loss of TH expression (Fig. 1E,F). Quantification of the number
of TH-positive cells revealed a significant 73% decrease in the
number of TH-positive neurons in the SNc of DAT-DTA mice
compared with control mice at P0 (Fig. 1D). The remaining TH-
positive cells appeared abnormal compared with TH-positive
cells in the SNc of control mice at this stage (Fig. 2E,F,H). Re-
maining neurons had neurites with large varicose swellings (Fig.
2F). In addition, a large number of cells were swollen and ap-
peared to be disintegrating, suggesting active loss of neurons at
this time point (Fig. 2H). By 1.5 months of age, TH-positive cell
loss in the SNc of DAT-DTAmice was 90% compared with con-
trolmice (Fig. 1D). No additional cell loss relative to controlmice
was observed in the SNc through 12 months of age. Loss of TH-
positive cells was less in the VTA than in the SNc of DAT-DTA
mice at all ages analyzed as has been reported in PD patients and
in several animal models of PD (Dauer and Przedborski, 2003).
This pattern of cell loss in DAT-DTA mice is consistent with
reported lower levels of DAT expression in the VTA compared
with the SNc (Storch et al., 2004). Cell loss in the VTA was also
progressive. In the VTA of DAT-DTA mice, the number of TH-
positive cells was significantly decreased by 50% at P0 (Figs. 1D,
2A–D). By 1.5 months of age, 72% of TH-positive neurons were
lost in the VTA of DAT-DTA mice. The number of TH-positive
neurons in the VTA of DAT-DTA mice further declined by 85%
at 12 months of age (Figs. 1D, 2 I, J). At all ages examined, re-
Figure 2. Loss of TH-positive neurons in the ventral midbrain of DAT-DTAmice.A–D, Fewer
TH-positive neurons are observed in the SNc and VTA of DAT-DTA mice at P0 compared with
control mice. TH-positive neuron loss is less severe in the VTA at this age. E, F, H, At P0, TH-
positive neurons in the SNc of DAT-DTAmice (F,H ) appear abnormal comparedwith neurons in
the SNc of controlmice (E). TH-positive neurons in the SNc of DAT-DTAmice (F,H ) appear to be
actively degenerating (arrowheads) andhaveneuriteswith large varicose swellings (F, arrows).
G, TH-positive neurons in the locus ceruleus (LC) of DAT-DTA mice have a normal appearance.
I–L, At 12 months of age, fewer TH-positive neurons are observed in the SNc and VTA of
DAT-DTAmice compared with control mice. TH-positive neuron loss appears to bemore severe
at 12 months compared with P0 in both the SNc and VTA of DAT-DTA mice.
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maining TH-positive neurons in the SNc and VTA exhibited an
abnormal appearance, including nonsmooth, irregular profiles
and distended neurites with large varicose swellings (Fig. 2F,H).
As expected, degeneration was specific to dopaminergic neurons.
TH-positive noradrenergic neurons in the locus ceruleus of
DAT-DTAmice have a normal morphology (Fig. 2G) and do not
appear to be decreased in number compared with control mice,
demonstrating thatDTA expression is restricted to dopaminergic
(DAT-positive) neurons.
In contrast to other models of dopaminergic neuron damage
(Breese and Traylor, 1972; Zhou and Palmiter, 1995; Kobayashi
et al., 2004), we did not observe dramatic weight loss and wasting
in DAT-DTA mice (Fig. 1B,C). Wasting in some of these prior
studies has been attributed to abnormalities in the hypothalamus
and/or damage to dopaminergic neurons in the gastrointestinal
(GI) tract (Kobayashi et al., 2004). InDAT-DTAmice, expression
of the DTA toxin is dependent on DAT-Cre expression. DAT is
expressed at significantly lower levels in dopaminergic neurons of
the hypothalamus compared with dopa-
minergic neurons in themidbrain (Storch
et al., 2004). We counted TH-positive
neurons in the nuclei of the hypothala-
mus. We found no significant difference
in the number of TH-positive neurons in
the hypothalamus of 5-month-old DAT-
DTA mice compared with control mice
(Fig. 3A). In addition, the morphology of
TH-positive neurons is similar in the hy-
pothalamus of DAT-DTA and control
mice (Fig. 3B,C).
DAT expression is also reportedly
lower in the gut compared with the brain
(Li et al., 2004).We examined TH-labeled
intrinsic dopaminergic neurons in the ter-
minal ileum of DAT-DTA and control
mice. We found that both the apparent
density and morphological appearance of
TH-labeled dopaminergic neurons in the
terminal ileum was similar in DAT-DTA
mice and control mice (Fig. 3D,E).
Locomotor activity is not impaired in
DAT-DTA mice
Locomotor activity in an open field has
been frequently used as a measure of
motor impairment following neurotoxin-
induced damage to midbrain dopaminer-
gic neurons and in rodent genetic models
of PD (Dunnett and Lelos, 2010; Taylor et
al., 2010). Surprisingly, open-field activity
was not different in DAT-DTAmice com-
pared with control mice at 1.5, 5, 12, or
18–24months of age. The total number of
horizontal movements, distance traveled,
and time spent moving were not different
during the 1 h testing period inDAT-DTA
mice compared with age-matched or lit-
termate control mice (Fig. 4A–C). We did
observe an age-dependent decrease in all
threemeasures of spontaneous locomotor
activity in control mice as reported previ-
ously (Gage et al., 1984; Da Silva Costa et
al., 2009) and in DAT-DTA mice.
Performance on the Rotarod is not impaired in DAT-
DTA mice
At 5 (Fig. 4D) and 12 (Fig. 4E)months of age, the time spent on an
accelerating Rotarod was not different in each of five consecutive
trials for DAT-DTAmice comparedwith controlmice. However,
both control mice (Fig. 4G) and DAT-DTA mice (Fig. 4H) ex-
hibited an age-dependent decrease in the amount of time on the
accelerating Rotarod between 5 and 12 months and between 5
and 18–24 months. At 18–24 months of age, performance of
DAT-DTAmice in Trial 1 on the Rotarod was not different from
control mice, suggesting equivalent motor ability in the two
groups (Fig. 4F). However, 18–24-month-old DAT-DTA mice
were not able to remain on the accelerating rod for as long as
control mice in the second through fifth trials. The performance
of control mice improved between Trial 1 and Trials 3–5 while
the performance ofDAT-DTAmice did not improve after Trial 1.
This result suggests the possibility that the differences between
Figure3. Dopaminergic neurons are normal in the hypothalamus and ileumofDAT-DTAmice.A, Counts of TH-positive neurons
in the nuclei of the hypothalamus reveal no significant differences in neuron number between 5-month-old control mice and
DAT-DTA mice. Pe, Periventricular and paraventricular nucleus; Arc, arcuate nucleus; DM, dorsomedial nucleus; PH, posterior
hypothalamus; PAG,periaqueductal gray; Thal, dorsal thalamus (mean
SEM,Student’s t test,p0.05;N3controlmice,N
3 DAT-DTAmice). B, C, TH-positive neurons in the arcuate nucleus of 5-month-old control mice (B) and DAT-DTAmice (C) appear
similar.D, E, TH-positive neurons in the ileumof controlmice (D) and DAT-DTAmice (E) appear similar inmorphology and density.
Representative images are from one of three control and one of three DAT-DTA mice examined.
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DAT-DTA and control mice in Trials 2–5 may be due to a learn-
ing impairment in aged DAT-DTA mice. Learning deficits have
been observed in rats depleted of dopamine in the neonatal pe-
riod (Shaywitz et al., 1976; Whishaw et al., 1987; Archer et al.,
1988).
Sensorimotor function is not impaired in DAT-DTA mice
To determine whether the extensive loss of SNc dopaminergic
neurons alters sensorimotor behavior of adult or agedDAT-DTA
mice, we performed a battery of sensorimotor tests. The pole test
is used to evaluate performance of a complex motor task that
requires skilled forelimb use, strength, and balance (Meredith
and Kang, 2006). At all ages studied, DAT-DTA mice were not
different from control mice either in the time required to turn
around and orient downward on a vertical pole (Fig. 5A) or the
time required to climb down from the pole (Fig. 5B). We did
observe an age-related increase in the time to orient down-
ward and the time to climb down in both control and DAT-
DTA mice.
The platform test evaluates balance and the ledge test evalu-
ates balance and strength. The performance of DAT-DTA mice
(N  13 control, 12 DAT-DTA) in the platform and ledge tests
was not different from age-matched controlmice at any age stud-
ied (data not shown). Tests designed to evaluate the initiation and
speed ofmovement, includingmeasurement of the time required
to leave the center of a square (18 18 cm; Fig. 5C) or the time
required to reach the top of a screen inclined at 60 or 90° from the
horizontal (data not shown) revealed no significant differences in
performance between DAT-DTA mice and control mice at any
age studied. PD patients exhibit decreased muscle strength that
Figure4. DAT-DTAmice do not showmotor behavior deficits comparedwith controlmice.A–C, Open-field test: DAT-DTAmice are not significantly different from controlmice at any age studied
(mean
 SEM, 2-WayANOVA,Bonferroni post-test,p0.05). Controlmice at 1.5months exhibit significantly greater locomotor activity comparedwith12-month-old controlmice (distance, time,
activity, p 0.05). DAT-DTAmice an 1.5months exhibit significantly greater locomotor activity comparedwith 12-month-old DAT-DTAmice (distance, time, p 0.001; activity, p 0.01). Control
mice at 1.5 months exhibit significantly greater locomotor activity compared with 18–24-month-old control mice (activity, p 0.05). DAT-DTA mice at 1.5 months exhibit significantly greater
locomotor activity compared with 18–24-month-old DAT-DTA mice (distance, p 0.01; time, p 0.001; activity, p 0.05). Control mice at 5 months exhibit significantly greater locomotor
activity compared with 12-month-old control mice (distance, time, activity, p 0.001). DAT-DTA mice at 5 months exhibit significantly greater locomotor activity compared with 12-month-old
DAT-DTA mice (time, p 0.05). Control mice at 5 months exhibit significantly greater locomotor activity compared with 18–24-month-old control mice (distance, time, activity, p 0.001).
Two-wayANOVA, Bonferroni post-testwas used for all the above comparisons. Fivemonths,N 9 controlmice, 8 DAT-DTAmice; 12months:N 9 controlmice, 12DAT-DTAmice; 18–24months:
N 8 controlmice, 6 DAT-DTAmice.D–H, Rotarod test: two-way ANOVA, Bonferroni post-test was used for all the following comparisons. Performance on the Rotarod is not different for DAT-DTA
mice compared with control mice at 5 or 12months (D, E, p 0.05). At 18–24months, the performance of DAT-DTAmice is significantly less than control mice in Trials 2–5 (F, *p 0.05, **p
0.01, ***p 0.001). At 18–24months, the performance of control mice is significantly better in Trials 3–5 comparedwith Trial 1 (F, Trial 1 vs 3, p 0.01; Trial 1 vs 4, p 0.001; Trial 1 vs 5, p
0.01). The performance of 18–24-month-old DAT-DTAmice is not significantly different between any of the five trials (F, p 0.05). Five-month-old control mice perform significantly better than
12 or 18–24month control mice. Fivemonth DAT-DTAmice perform significantly better than 12 or 18–24month DAT-DTAmice (G,H, *p 0.05, **p 0.01, ***p 0.001). Fivemonths: N
13 control mice, 12 DAT-DTA mice; 12 months: N 9 control mice, 12 DAT-DTA mice; 18–24 months: N 11 control mice, 6 DAT-DTA mice.
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may be a secondary consequence of decreased activity or a direct
result of dopamine loss (Cano-de-la-Cuerda et al., 2010). We
used the inverted screen test to evaluate muscle strength in DAT-
DTA mice (Tillerson et al., 2002; Fig. 5D). At 5 months of age,
DAT-DTA mice remained on the inverted screen for the same
amount of time as control mice. At 12 and 18–24 months,
DAT-DTA mice performed better than control mice, remain-
ing on the screen twice as long as control mice. This result
suggests that DAT-DTA mice do not exhibit decreased muscle
strength. We also observed an age-dependent decrease in the
amount of time on the inverted screen for both control and
DAT-DTA mice.
Figure 5. Motor behavior and gait are not impaired in DAT-DTAmice compared with control mice. A, B, Pole test: performance in the pole test is not different in DAT-DTAmice compared with
control mice at any age studied (mean
 SEM. Student’s t test). There is an age-dependent decrease in performance on the pole test in both DAT-DTA and control mice (2-Way ANOVA, Bonferroni
post-test). Pole turn around (A): control mice: 5 vs 12months, Trial 1: p 0.001; Trial 2: p 0.05; 5 vs 18–24months, Trial 1: p 0.001; Trial 2: p 0.001. DAT-DTAmice: 5 vs 12months, Trial
1: p 0.001; Trial 2: p 0.01; 5 vs 18–24months, Trial 1: p 0.05; Trial 2: p 0.05. Pole climb down (B): control mice: 5 vs 12months, Trial 1: p 0.05; Trial 2: p 0.05; 5 vs 18–24months,
Trial 1: p 0.001; Trial 2: p 0.01. DAT-DTAmice: 5 vs 12months, Trial 1: p 0.05; Trial 2: p 0.05; 5 vs 18–24months, Trial 1: p 0.05; Trial 2: p 0.05. Fivemonths: N 13 control mice,
N 12 DAT-DTAmice; 12months: N 9 control mice, N 12 DAT-DTAmice; 18–24months: N 8 control mice, N 6 DAT-DTAmice. C, Movement-initiation test: movement initiation is not
significantly different inDAT-DTAmice comparedwith controlmice at any age studied (mean
 SEM, Student’s t test, p0.05). Fivemonths:N9 controlmice,N7DAT-DTAmice; 12months:
N 9 control mice, N 12 DAT-DTAmice; 18–24months: N 8 control mice, N 6 DAT-DTAmice. D, Inverted screen test: at 5 months, time on an inverted screen is not different in DAT-DTA
mice comparedwith control mice (mean
 SEM, Student’s t test, p 0.05). At 12 and 18–24months DAT-DTAmice remain on an inverted screen significantly longer than control mice (mean

SEM, Student’s t test, *p 0.05). There is an age-dependent decrease in performance on the inverted screen test in control mice: Trial 1: 5 vs 12months, p 0.01; 5 vs 18–24months, p 0.01;
Trial 2: 5 vs 12 months, p 0.05; 5 vs 18–24 months, p 0.01 (mean
 SEM, 2-Way ANOVA, Bonferroni post-test). Five months: N 9 control mice, N 7 DAT-DTA mice; 12 months: N 9
controlmice,N 12DAT-DTAmice; 18–24months,N 7 controlmice,N 6DAT-DTAmice. E, F, Footprint test: there is no difference in SWor SL betweenDAT-DTAmice and controlmice at any
age studied (mean
SEM,Student’s t test,p0.05). Threemonths:N5controlmice,N4DAT-DTAmice; 4– 6months:N8controlmice,N8DAT-DTAmice; 8–14months:N4control
mice, N 3 DAT-DTA mice; 18 months: N 6 control mice, N 3 DAT-DTA mice.
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Gait analysis
Gait analysis has been used previously to
document motor impairment in a num-
ber of rodentmodels, includingmodels of
nigrostriatal dysfunction (Tillerson et al.,
2002; Byler et al., 2009; Taylor et al.,
2010). Our analysis revealed no differ-
ences in SW (Fig. 5E) or SL (Fig. 5F) in
DAT-DTA mice compared with age-
matched control mice at any age studied.
In addition, measures of paw length, TS,
and ITS were not different between DAT-
DTA mice and control mice at any age
studied (data not shown).
Marked reduction in TH-positive fiber
density in the dorsal and ventral
striatum of DAT-DTA mice
The absence of motor behavior deficits
in DAT-DTA mice, despite near com-
plete loss of SNc dopaminergic neurons,
prompted us to evaluate dopaminergic in-
nervation of the striatum. We examined
TH-positive fibers in the dorsal and ven-
tral striatum of DAT-DTA mice to deter-
mine whether dopaminergic cell loss in
the SNc and VTA is accompanied by loss
of striatal dopaminergic afferents. At P0,
TH-positive striatal afferents are greatly
reduced in the dorsal striatum of DAT-
DTA mice compared with control mice
(Fig. 6A,B). At this age, fiber density is
also reduced in the ventral striatum of
DAT-DTA mice, but the reduction in the
ventral striatum appears less severe than
the reduction in the dorsal striatum (Fig.
6B, arrow). TH-positive fiber density ap-
pears to be further decreased in the dorsal
striatum of DAT-DTA mice at 5 (Fig.
6D,E) and 12 months of age (data not
shown), which is consistent with the in-
creased loss of dopaminergic neurons from the SNc after P0 (Fig.
1D). We quantified the areal fraction of TH-positive fibers in the
dorsal and ventral striatum of 5-month-old DAT-DTA and con-
trol mice using an unbiased stereological method as previously
described (Gundersen et al., 1988; Jain et al., 2006). At 5 months
of age, TH-positive fiber density is decreased by 93% in the
dorsal striatum of DAT-DTA mice compared with control mice
(Fig. 6C–E). At this age, TH-positive fiber density is decreased by
58% in the ventral striatum of DAT-DTAmice compared with
control mice (Fig. 6C,F,G). The more severe fiber loss in the
dorsal striatum compared with the ventral striatum (p 0.001)
is consistent with the greater magnitude of SNc cell loss com-
pared with VTA cell loss at this age (Fig. 1D).
Biochemical analysis reveals a marked reduction of striatal
dopamine in DAT-DTA mice
Compensatory mechanisms that maximize dopaminergic trans-
mission have been identified following damage to the nigrostria-
tal dopaminergic pathway (Zigmond et al., 1984, 1990). These
include increased dopamine synthesis and increased dopamine
release (suggested by an increase in the ratio of dopaminemetab-
olites to dopamine). We used HPLC to quantify dopamine and
the dopamine metabolites HVA and DOPAC in the dorsal stria-
tum of DAT-DTA and control mice. Dopamine, DOPAC, and
HVA are significantly decreased in the dorsal striatum of DAT-
DTA mice compared with control mice at 2, 5–7, and 12–24
months of age (Fig. 7A). The ratio of DOPAC to dopamine was
not different in DAT-DTA mice compared with control mice at
any age studied (Fig. 7B). At 2months of age, the ratio of HVA to
dopamine was not significantly different in DAT-DTA mice
compared with control mice (Fig. 7C). However, at 5–7 and
12–24 months of age, the ratio of HVA to dopamine was signifi-
cantly increased in DAT-DTAmice compared with control mice.
Dopamine depletion in the dorsal striatumofDAT-DTAmice
is nearly complete (97%) at 2months, suggesting that dopamine-
independentmechanisms could be responsible for normalmotor
behavior in DAT-DTA mice. To determine whether the normal
motor behavior of DAT-DTA mice is dependent on residual do-
pamine, we treated 12-month-old male and female DAT-DTA
and control mice with the dopamine receptor antagonist halo-
peridol and evaluated motor behavior. As expected, haloperidol
treatment resulted in a significant decrease in the locomotor ac-
tivity of 12-month-old control mice in the open-field test com-
pared with vehicle (DMSO)-treated control mice (Fig. 8A).
Figure 6. Loss of TH-positive fibers in the dorsal and ventral striatum of DAT-DTA mice. A, B, At P0, TH-positive fibers are
decreased in the dorsal striatum of DAT-DTA mice compared with control mice. TH-positive fiber density is less affected in the
ventral striatum of DAT-DTAmice (B, arrow). Thewhite dotted line in A andB outlines the area of the dorsal and ventral striatum.
C, Quantification of TH-positive fiber density in the striatum of 5-month-old mice reveals a significant decrease in fiber density in
both the dorsal and ventral striatumof DAT-DTAmice comparedwith controlmice (mean
 SEM, Student’s t test, ***p 0.001).
N 3 control mice, N 3 DAT-DTA mice. D–G, Representative images used for quantifying fiber density showing decreased
TH-positive fiber density in both the dorsal and ventral striatum of DAT-DTA mice compared with control mice.
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Haloperidol-treated control mice were similarly impaired in the
movement-initiation test (Fig. 8A) and the catalepsy test (data
not shown) compared with vehicle-treated control mice. The
performance of 12-month-old haloperidol-treated DAT-DTA
mice was not different from haloperidol-treated littermate con-
trolmice in the open-field test (Fig. 8A), themovement-initiation
test (Fig. 8A), or the catalepsy test (data not shown). These results
indicate that maintenance of normal motor behavior in DAT-
DTAmice is dependent on the small amount of remaining striatal
dopamine (3% of control; Fig. 7A) in DAT-DTA mice.
Previous studies have shown that dopamine receptor agonists
induce an exaggerated increase in locomotor activity in animals
with nigrostriatal damage. The increased activity in response to
dopamine agonists observed in injured animals is reportedly due
to sensitization of striatal dopamine receptors (Zigmond and
Stricker, 1980; Breese et al., 1985; Brotchie and Fitzer-Attas,
2009). To gain insight into the mechanism by which motor be-
havior is preserved in DAT-DTA mice, we treated 6–7-month-
old DAT-DTA mice and control mice with L-DOPA (25 mg/kg)
and measured locomotor activity. This dose of L-DOPA did not
alter the locomotor activity of control mice in the open-field test
compared with vehicle-treated control mice (Fig. 8B). The loco-
motor activity of L-DOPA-treated DAT-DTA mice was signifi-
cantly increased compared with L-DOPA-treated control mice
(Fig. 8B). The observed increase in locomotor activity in DAT-
DTA mice compared with control mice in response to L-DOPA
suggests that striatal dopamine receptors are functionally sensi-
tized in DAT-DTA mice. This sensitization likely contributes to
the preservation of motor behavior observed in these mice.
Movement initiation was not altered in either DAT-DTAmice or
control mice in response to L-DOPA (Fig. 8B).
To determine whether increased expression of dopamine re-
ceptors contributes to functional sensitization, we evaluated the
expression of dopamine receptors in 12-month-old DAT-DTA
mice using qRT-PCR. Our analysis shows no change in the ex-
pression of either D1 or D2 dopamine receptors in the dorsal
striatum of DAT-DTA mice compared with control mice (data
not shown). The observed functional sensitization in response to
L-DOPA may be a result of mechanisms that regulate the trans-
lation of dopamine receptors, the post-translational modifica-
tion of receptors, or receptor trafficking. Additional studies will
be required to evaluate the contribution of these potential
changes to sensitization.
Discussion
DTA expressed from the DAT locus produces a substantial and
reproducible loss of SNc dopaminergic neurons and striatal do-
pamine in DAT-DTA mice without the systemic toxicity, dosing
limitations, or lack of specificity inherent inmodels using neuro-
toxins to destroy dopaminergic neurons (Blandini and Arment-
ero, 2012). Despite loss of 90% of SNc dopaminergic neurons,
dysfunction of surviving neurons (as inferred from degenerative
morphological changes), and depletion of 97% of striatal dopa-
mine, we were not able to detect motor behavior defects in DAT-
DTAmice using behavior tests that have been used previously to
demonstrate motor dysfunction in other models of nigrostriatal
damage (Meredith andKang, 2006; Byler et al., 2009; Taylor et al.,
2010). Importantly, we were able to detect an age-dependent
decline in motor performance in both control and DAT-DTA
mice, demonstrating that our testing methods are sufficient to
detect motor dysfunction. Our results indicate that preserved
motor function in DAT-DTA mice is dependent on residual do-
pamine.Other, nondopaminergicmechanismsmay also contrib-
ute to themaintenance ofmotor function inDAT-DTAmice, but
such mechanisms are insufficient to maintain normal motor be-
havior when dopaminergic transmission is blocked by haloperi-
dol. Previous studies in which dopaminergic neurons have been
destroyed by administration of toxins to adult animals have
found motor behavior deficits with far less severe SNc neuron
loss and striatal dopamine depletion than those seen in DAT-
DTAmice (Bove´ and Perier, 2012). However, themajority of SNc
dopaminergic neurons (70%) are lost in DAT-DTA mice dur-
ing prenatal development. Our results show that the nigrostriatal
dopaminergic pathway has a significant capacity to compensate
for damage sustained during prenatal development. The remark-
able preservation of motor function in DAT-DTA mice that oc-
curs in the absence of growth retardation andnonspecific damage
to nondopaminergic pathways suggests that additional mecha-
nisms of plasticity may be induced when damage occurs in devel-
oping animals. Identification of the molecular mechanisms that
underlie motor behavior sparing in DAT-DTAmice may suggest
Figure 7. Dopamine, DOPAC, and HVA are depleted in the dorsal striatum of DAT-DTAmice.
A, Dopamine, DOPAC, and HVA are decreased in the dorsal striatum of DAT-DTAmice compared
with controlmice at all ages studied (mean
 SEM, Student’s t test, control vs DAT-DTA at each
time point; *p 0.05, **p 0.01, ***p 0.001). B, The ratio of DOPAC to dopamine is not
significantly different between DAT-DTA mice and control mice at any age studied (mean

SEM, Student’s t test, p 0.05). C, The ratio of HVA to dopamine is significantly increased in
DAT-DTA mice compared with control mice at 5–7 and 12–24 months of age (mean
 SEM,
Student’s t test, **p0.01). Twomonths:N5of eachgenotype; 5–7months:N3of each
genotype; 12–24 months: N 5 control mice, 4 DAT-DTA mice.
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novel strategies for treating PD or for improving current
therapies.
Studies in which prenatal exposure to a neurotoxin was used
to damage the nigrostriatal system have found that less severe
damage, compared with that seen in DAT-DTA mice, results in
defects inmotor performance. For example, prenatal administra-
tion of MPTP reduces striatal dopamine by14% and results in
decreased spontaneous locomotion (Muthian et al., 2010). Pre-
natal administration of lipopolysaccharide produces a moderate
decrease in SNc dopaminergic neurons (30%; Ling et al., 2002,
2009; Carvey et al., 2003) and results in decreased locomotion in
the open field and an increased number of skips in the beam-
walking test (Bakos et al., 2004). These findings are consistent
with the idea that damage to dopaminergic neurons during pre-
natal development can result in motor behavior defects in adult
animals. A much greater percentage of SNc dopaminergic neu-
rons are destroyed during prenatal development in DAT-DTA
mice. A greater magnitude of neuron loss may be required to
induce mechanisms of compensation. It is also possible that tox-
icity to the mother or other unknown effects of the toxin in the
fetus could affect motor behavior in animals treated prenatally
with toxins.
Moderate feeding andmotor behavior deficits occur in rats in
which 6-OHDA is used to damage dopaminergic neurons during
early postnatal development (Breese et al., 2005). Adult rats sus-
taining 95% depletion of striatal dopamine following intrac-
erebralventricular or intranigral administration of 6-OHDA
exhibit adipsia, aphagia, and akinesia (Ungerstedt, 1971; Zig-
mond and Stricker, 1973; Marshall et al., 1974). Although rats
treated with intracerebralventricular 6-OHDA as neonates (P3)
sustain comparable depletion of striatal dopamine as adult-
treated rats, they exhibit much less severe feeding and motor
behavior defects. Locomotor behavior is reportedly increased
(Shaywitz et al., 1976; Erinoff et al., 1979, 1984; Archer et al.,
1988) or decreased (Smith et al., 1973) in adult rats treated with
6-OHDA as neonates. In addition, defects in skilled forearm and
tongue use have been observed in these rats (Whishaw et al.,
1987). In contrast to neonatal-treated 6-OHDA rats that have
some motor behavior deficits, we were not able to detect any
deficits in motor behavior in DAT-DTA mice that sustained
comparable depletion of striatal dopamine. This difference may
be related to the time course of SNc cell damage in the two mod-
els, to species differences, or to other effects of the toxin. In
addition to dopaminergic neurons, 6-OHDA also damages nor-
adrenergic neurons (Ungerstedt, 1968). Damage to noradrener-
gic neurons alone increases locomotor behavior (Smith et al.,
1973). Although, desmethylimipramine (DMI) is routinely ad-
ministered with 6-OHDA to minimize damage to noradrenergic
neurons,DMI is not completely effective in preventing damage to
noradrenergic neurons (Breese and Traylor, 1971; Castan˜eda et
al., 1990). In addition, mice treated with 6-OHDA at early post-
natal stages show marked growth retardation, which could im-
pact motor behavior (Breese and Traylor, 1972). Our data show
normal motor behavior in a mouse model in which substantial
Figure 8. DAT-DTAmice are sensitive to haloperidol and hypersensitive to L-DOPA.A, Haloperidol (1mg/kg) significantly decreases locomotor activity in both DAT-DTAmice and control mice at
12 months of age. Locomotor activity is not significantly different in haloperidol-treated DAT-DTA mice compared with haloperidol-treated control mice. The time required to exit an 18 18 cm
square is significantly increased in haloperidol-treated DAT-DTA mice and haloperidol-treated control mice compared with vehicle-treated control mice. Exit time is not significantly different in
haloperidol-treatedDAT-DTAmice comparedwith haloperidol-treated controlmice.Mean
 SEM, Student’s t test, control vs DAT-DTA, *p 0.05, **p 0.01, ***p 0.001. Controlmice/DMSO,
N 2; controlmice/haloperidol,N 7; DAT-DTAmice/haloperidol,N 7.B, The locomotor activity of L-DOPA-treated controlmice is not significantly different from vehicle-treated controlmice.
The locomotor activity of L-DOPA-treated DAT-DTA mice is significantly increased compared with L-DOPA-treated control mice. The time required to exit an 18 18 cm square is not significantly
different in L-DOPA-treated DAT-DTA mice compared with L-DOPA-treated control mice. Mean
 SEM, Student’s t test, control vs DAT-DTA, *p 0.05, **p 0.01, ***p 0.001. Control
mice/vehicle, N 4; control mice/L-DOPA, N 5; DAT-DTA mice/L-DOPA, N 7.
17104 • J. Neurosci., October 23, 2013 • 33(43):17095–17107 Golden et al. • Dopamine-Dependent Compensation
damage specifically to dopaminergic neurons is sustained during
prenatal development in the absence of adverse effects on general
health.
Rats treated with 6-OHDA as neonates are resistant to halo-
peridol treatment in adulthood, suggesting that nondopaminergic
systems are compensating for the loss of dopamine to maintain
normal motor behavior in these rats (Bruno et al., 1985; Duncan
et al., 1987; Weihmuller and Bruno, 1989). In contrast, our re-
sults indicate that with comparable depletion of striatal dopa-
mine, residual dopamine is responsible for the maintenance of
normal motor behavior in DAT-DTA mice. It is surprising that
normal motor behavior in DAT-DTA mice is dependent on re-
sidual dopamine. TH-positive fibers are virtually absent in the
striatum of adult DAT-DTA mice and striatal dopamine is de-
creased by 97%, indicating nearly complete depletion of dopa-
mine. Preservation of motor behavior following partial damage
to the nigrostriatal system is thought to be due to adaptations in
residual dopaminergic terminals, such as increased dopamine
synthesis and release and attenuated dopamine reuptake (Zig-
mond et al., 1984, 1990). In addition, changes in postsynaptic
striatal neurons can also maximize dopaminergic transmission
when dopamine levels are severely depleted.
Increased dopamine release is reflected by an increase in the
ratio of dopamine metabolites to dopamine, particularly the
HVA/dopamine ratio. DAT-DTA mice have a significantly
greater HVA/dopamine ratio, which is consistent with the hy-
pothesis that maintenance of motor function in DAT-DTAmice
is dependent upon mechanisms that maximize the efficiency
of residual dopamine. However, dopamine-dependent mecha-
nisms that preserve normal motor behavior in animals with par-
tial nigrostriatal damage are reportedly limited. Previous studies
indicate that these mechanisms are only effective when5–10%
of dopaminergic terminals remain in the striatum (Reader and
Dewar, 1999). In addition, the nigrostriatal system is more sus-
ceptible to toxin-induced damage in aged animals and compen-
satory mechanisms that maximize dopamine function are
attenuated in aged animals (Ovadia et al., 1995; Thiruchelvam et
al., 2003; Collier et al., 2007, 2011; Peng et al., 2007). It is therefore
surprising that nomotor defects are observed inDAT-DTAmice,
even at 18–24 months of age, and that aged DAT-DTA mice are
sensitive to haloperidol, suggesting that compensatory mecha-
nisms that rely on residual dopamine are intact even in aged
DAT-DTAmice. Our results further indicate that themechanism
underlying preservation of motor behavior in DAT-DTA mice
involves functional sensitization of dopamine receptors.
Interestingly, developmental elimination of dopaminergic
transmission by deletion of TH or D1 and D2 dopamine recep-
tors results in more severe behavior deficits than destruction of
dopaminergic neurons in DAT-DTA mice. Dopamine-deficient
mice are hypoactive, exhibit severe growth retardation, and die
during the third postnatal week (Zhou and Palmiter, 1995). Mice
in which both the D1 and D2 dopamine receptors are deleted
have a similar phenotype to dopamine-deficient mice and also
die in the third postnatal week (Kobayashi et al., 2004). Prema-
ture death of D1/D2-null mice is thought to be due to peripheral
GI defects that result in a failure to thrive and severe growth
retardation. In contrast, DAT-DTA mice are generally healthy
and appear to grow and develop normally. The absence of severe
growth retardation in DAT-DTAmice may be due to lower DAT
expression and thus lower DAT-CRE activity in peripheral dopa-
minergic neurons, which results in less DTA-mediated cell dam-
age in the GI system (Li et al., 2004). Our observation that
intrinsic dopaminergic neurons in the terminal ileum appear
similar in DAT-DTA mice and control mice is consistent with
this possibility. In addition, we observed no significant loss of
dopaminergic neurons in the hypothalamus of DAT-DTA mice
compared with control mice. Since DAT expression is also re-
ported to be significantly lower in hypothalamic dopaminergic
neurons compared with midbrain dopaminergic neurons
(Storch et al., 2004), this observation also supports the hypothesis
that expression of the DTA toxin is lower in dopaminergic neu-
rons with low DAT expression. The olfactory bulbs contain a
large number of dopaminergic neurons inwhichDAT expression
is also reportedly low (Cerruti et al., 1993; Fujita et al., 1993). It
will be interesting to determinewhether these neurons are altered
in DAT-DTA mice. It is also possible that dopaminergic trans-
mission is more significantly impaired in dopamine-deficient
and D1/D2-null mice compared with DAT-DTA mice. Studies
using microdialysis show that the decrease in extracellular dopa-
mine concentration is not as severe as the decrease in tissue do-
pamine following neonatal 6-OHDA treatment (Castan˜eda et al.,
1990). Therefore, although striatal dopamine is decreased by 97%
in DAT-DTA mice, extracellular dopamine may not be entirely
depleted in these mice.
Our studies reveal remarkable preservation ofmotor behavior
inmice with severe loss of SNc dopaminergic neurons and nearly
complete depletion of striatal dopamine. The observation that
preserved motor behavior depends on mechanisms that require
intact dopaminergic transmission in aged DAT-DTA mice sug-
gests even greater plasticity of the nigrostriatal dopaminergic
pathway than previously thought. The DAT-DTA mouse is a
novel model for studying the behavioral effects of dopamine de-
pletion in the absence of motor impairment or growth retarda-
tion. For example, studies examining the role of dopaminergic
pathways in addiction and in the regulation of circadian rhythm
use behavioral assays, such as conditioned place preference and
voluntary wheel running, that depend on intact motor function.
Interpretation of these assays is complicated by impaired motor
performance in neurotoxin models of dopaminergic neuron
damage. The DAT-DTAmouse provides an opportunity to eval-
uate the effects of damage to dopaminergic pathways in the ab-
sence of motor dysfunction.
References
Archer T, Danysz W, Fredriksson A, Jonsson G, Luthman J, Sundstro¨m E,
Teiling A (1988) Neonatal 6-hydroxydopamine-induced dopamine de-
pletions: motor activity and performance in maze learning. Pharmacol-
ogy, biochemistry, and behavior 31:357–364. CrossRef Medline
Bakos J, Duncko R, Makatsori A, Pirnik Z, Kiss A, Jezova D (2004) Prenatal
immune challenge affects growth, behavior, and brain dopamine in off-
spring. Ann N Y Acad Sci 1018:281–287. CrossRef Medline
Barlow BK, Cory-Slechta DA, Richfield EK, Thiruchelvam M (2007) The
gestational environment and Parkinson’s disease: evidence for neurode-
velopmental origins of a neurodegenerative disorder. Reprod Toxicol 23:
457–470. CrossRef Medline
Blandini F, Armentero MT (2012) Animal models of Parkinson’s disease.
FEBS J 279:1156–1166. CrossRef Medline
Bove´ J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease.
Neuroscience 211:51–76. CrossRef Medline
BreeseGR,TraylorTD (1971) Depletionof brainnoradrenaline anddopamine
by 6-hydroxydopamine. Br J Pharmacol 42:88–99. CrossRefMedline
Breese GR, Traylor TD (1972) Developmental characteristics of brain cat-
echolamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopa-
mine. Br J Pharmacol 44:210–222. CrossRefMedline
Breese GR, Napier TC, Mueller RA (1985) Dopamine agonist-induced lo-
comotor activity in rats treated with 6-hydroxydopamine at differing ag-
es: functional supersensitivity of D-1 dopamine receptors in neonatally
lesioned rats. J Pharmacol Exp Ther 234:447–455. Medline
BreeseGR, KnappDJ, Criswell HE,Moy SS, Papadeas ST, Blake BL (2005) The
Golden et al. • Dopamine-Dependent Compensation J. Neurosci., October 23, 2013 • 33(43):17095–17107 • 17105
neonate-6-hydroxydopamine-lesioned rat: amodel for clinical neuroscience
and neurobiological principles. Brain Res Brain Res Rev 48:57–73. CrossRef
Medline
Brotchie J, Fitzer-Attas C (2009) Mechanisms compensating for dopamine
loss in early Parkinson disease. Neurology 72:S32–S38. CrossRef Medline
Bruno JP, Stricker EM, ZigmondMJ (1985) Rats given dopamine-depleting
brain lesions as neonates are subsensitive to dopaminergic antagonists as
adults. Behav Neurosci 99:771–775. CrossRef Medline
Byler SL, Boehm GW, Karp JD, Kohman RA, Tarr AJ, Schallert T, Barth TM
(2009) Systemic lipopolysaccharide plus MPTP as a model of dopamine
loss and gait instability in C57BL/6J mice. Behav Brain Res 198:434–439.
CrossRef Medline
Cano-de-la-Cuerda R, Pe´rez-de-Heredia M, Miangolarra-Page JC, Mun˜oz-
Hellín E, Ferna´ndez-de-Las-Pen˜as C (2010) Is there muscular weakness
in Parkinson’s disease? Am J Phys Med Rehabil 89:70–76. CrossRef
Medline
Carvey PM, Chang Q, Lipton JW, Ling Z (2003) Prenatal exposure to the
bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine
neurons in offspring: a potential, newmodel of Parkinson’s disease. Front
Biosci 8:s826–837. CrossRef Medline
Castan˜eda E, Whishaw IQ, Lermer L, Robinson TE (1990) Dopamine de-
pletion in neonatal rats: effects on behavior and striatal dopamine release
assessed by intracerebral microdialysis during adulthood. Brain Res 508:
30–39. CrossRef Medline
Cerruti C, Walther DM, Kuhar MJ, Uhl GR (1993) Dopamine transporter
mRNA expression is intense in rat midbrain neurons andmodest outside
midbrain. Brain Res Mol Brain Res 18:181–186. CrossRef Medline
Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, Bakay RA, Sladek JR Jr,
Kordower JH 2007 Aging-related changes in the nigrostriatal dopamine
system and the response toMPTP in nonhuman primates; diminished com-
pensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26:56–
65. Medline
Collier TJ, KanaanNM,Kordower JH (2011) Ageing as a primary risk factor
for Parkinson’s disease: evidence from studies of non-human primates.
Nat Rev Neurosci 12:359–366. CrossRef Medline
Da Silva Costa V, Duchatelle P, Boulouard M, Dauphin F (2009) Selective
5-HT6 receptor blockade improves spatial recognition memory and re-
verses age-related deficits in spatial recognition memory in the mouse.
Neuropsychopharmacology 34:488–500. CrossRef Medline
DauerW, Przedborski S (2003) Parkinson’s disease: mechanisms andmod-
els. Neuron 39:889–909. CrossRef Medline
Duncan GE, Criswell HE, McCown TJ, Paul IA, Mueller RA, Breese GR (1987)
Behavioral and neurochemical responses to haloperidol and SCH-23390 in
rats treated neonatally or as adults with 6-hydroxydopamine. J Pharmacol
Exp Ther 243:1027–1034. Medline
Dunnett SB, Lelos M (2010) Behavioral analysis of motor and non-motor
symptoms in rodent models of Parkinson’s disease. Prog Brain Res 184:
35–51. CrossRef Medline
Erinoff L, MacPhail RC, Heller A, Seiden LS (1979) Age-dependent effects
of 6-hydroxydopamine on locomotor activity in the rat. Brain Res 164:
195–205. CrossRef Medline
Erinoff L, Kelly PH, Basura M, Snodgrass SR (1984) Six-hydroxydopamine
induced hyperactivity: neither sex differences nor caffeine stimulation are
found. Pharmacol Biochem Behav 20:707–713. CrossRef Medline
Franklin BJ, PaxinosGT (1997) Themouse brain in stereotaxic coordinates.
Academic: New York.
Fujita M, Shimada S, Nishimura T, Uhl GR, Tohyama M (1993) Ontogeny
of dopamine transporter mRNA expression in the rat brain. Brain Res
Mol Brain Res 19:222–226. CrossRef Medline
Gage FH, Dunnett SB, Bjo¨rklund A (1984) Spatial learning and motor def-
icits in aged rats. Neurobiol Aging 5:43–48. CrossRef Medline
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperloco-
motion and indifference to cocaine and amphetamine inmice lacking the
dopamine transporter. Nature 379:606–612. CrossRef Medline
Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Møller A, Nielsen K,
Nyengaard JR, Pakkenberg B, Sørensen FB, Vesterby A (1988) Some
new, simple and efficient stereological methods and their use in patho-
logical research and diagnosis. APMIS 96:379–394. CrossRef Medline
Hickey P, Stacy M (2012) Adenosine A2A antagonists in Parkinson’s dis-
ease: what’s next? Curr Neurol Neurosci Rep 12:376–385. CrossRef
Medline
Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM Jr, Milbrandt J (2006)
RET is dispensable for maintenance of midbrain dopaminergic neurons
in adult mice. J Neurosci 26:11230–11238. CrossRef Medline
Kobayashi M, Iaccarino C, Saiardi A, Heidt V, Bozzi Y, Picetti R, Vitale C,
Westphal H, Drago J, Borrelli E (2004) Simultaneous absence of dopa-
mine D1 and D2 receptor-mediated signaling is lethal in mice. Proc Natl
Acad Sci U S A 101:11465–11470. CrossRef Medline
Li ZS, Pham TD, Tamir H, Chen JJ, Gershon MD (2004) Enteric dopami-
nergic neurons: definition, developmental lineage, and effects of extrinsic
denervation. J Neurosci 24:1330–1339. CrossRef Medline
Ling Z, Gayle DA,Ma SY, Lipton JW, Tong CW,Hong JS, Carvey PM (2002)
In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase
neurons in the postnatal rat midbrain. Mov Disorder 17:116–124.
CrossRef Medline
Ling Z, ZhuY, TongCW, Snyder JA, Lipton JW,Carvey PM (2009) Prenatal
lipopolysaccharide does not accelerate progressive dopamine neuron loss
in the rat as a result of normal aging. Exp Neurol 216:312–320. CrossRef
Medline
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25:402–408. CrossRef Medline
Marshall JF, Richardson JS, Teitelbaum P (1974) Nigrostriatal bundle dam-
age and the lateral hypothalamic syndrome. J Comp Physiol Psychol 87:
808–830. CrossRef Medline
Meredith GE, Kang UJ (2006) Behavioral models of Parkinson’s disease in
rodents: a new look at an old problem. Mov Disord 21:1595–1606.
CrossRef Medline
Mohajjel Nayebi AA, Sheidaei H (2010) Buspirone improves haloperidol-
induced Parkinson disease in mice through 5-HT1A receptors. DARU
18:41–45. Medline
Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED,
Gereau RW 4th (2009) The metabotropic glutamate receptor subtype 5
antagonist fenobam is analgesic and has improved in vivo selectivity com-
pared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-
pyridine. J Pharmacol Exp Ther 330:834–843. CrossRef Medline
MuthianG,MackeyV, King J, CharltonCG (2010) Modeling a sensitization
stage and a precipitation stage for Parkinson’s disease using prenatal and
postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Neuroscience 169:1085–1093. CrossRef Medline
Ovadia A, Zhang Z, Gash DM (1995) Increased susceptibility toMPTP tox-
icity in middle-aged rhesus monkeys. Neurobiol Aging 16:931–937.
CrossRef Medline
Pehek EA, Crock R, Yamamoto BK (1992) Selective subregional dopamine
depletions in the rat caudate-putamen following nigrostriatal lesions.
Synapse 10:317–325. CrossRef Medline
Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK (2007) Iron and
paraquat as synergistic environmental risk factors in sporadic Parkinson’s
disease accelerate age-related neurodegeneration. J Neurosci 27:6914–
6922. CrossRef Medline
Ponce FA, Lozano AM (2010) Deep brain stimulation state of the art and
novel stimulation targets. Prog Brain Res 184:311–324. CrossRefMedline
Reader TA, Dewar KM (1999) Effects of denervation and hyperinnervation
on dopamine and serotonin systems in the rat neostriatum: implica-
tions for human Parkinson’s disease. Neurochem Int 34:1–21.
CrossRef Medline
Shaywitz BA, Yager RD, Klopper JH (1976) Selective brain dopamine deple-
tion in developing rats: an experimentalmodel ofminimal brain dysfunc-
tion. Science 191:305–308. CrossRef Medline
Smith RD, Cooper BR, Breese GR (1973) Growth and behavioral changes in
developing rats treated intracisternally with 6-hydroxydopamine: evi-
dence for involvement of brain dopamine. J Pharmacol Exp Ther 185:
609–619. Medline
Storch A, Ludolph AC, Schwarz J (2004) Dopamine transporter: involve-
ment in selective dopaminergic neurotoxicity and degeneration. J Neural
Transm 111:1267–1286. CrossRef Medline
Taylor MD, Vancura R, Patterson CL, Williams JM, Riekhof JT, Wright DE
(2001) Postnatal regulation of limb proprioception by muscle-derived
neurotrophin-3. J Comp Neurol 432:244–258. CrossRef Medline
Taylor TN, Greene JG,Miller GW (2010) Behavioral phenotyping ofmouse
models of Parkinson’s disease. Behav Brain Res 211:1–10. CrossRef
Medline
Thiruchelvam M, McCormack A, Richfield EK, Baggs RB, Tank AW, Di
Monte DA, Cory-Slechta DA (2003) Age-related irreversible progres-
17106 • J. Neurosci., October 23, 2013 • 33(43):17095–17107 Golden et al. • Dopamine-Dependent Compensation
sive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb
model of the Parkinson’s disease phenotype. Eur J Neurosci 18:589–600.
CrossRef Medline
Tillerson JL, Caudle WM, Revero´n ME, Miller GW (2002) Detection of be-
havioral impairments correlated to neurochemical deficits inmice treated
with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Exp Neurol 178:80–90. CrossRef Medline
Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of cen-
tral monoamine neurons. Eur J Pharmacol 5:107–110. CrossRef Medline
Ungerstedt U (1971) Adipsia and aphagia after 6-hydroxydopamine in-
duced degeneration of the nigro-striatal dopamine system. Acta Physiol
Scand Suppl 367:95–122. Medline
Weihmuller FB, Bruno JP (1989) Drinking behavior and motor function in
rat pups depleted of brain dopamine during development. Dev Psycho-
biol 22:101–113. CrossRef Medline
Whishaw IQ, Funk DR, Hawryluk SJ, Karbashewski ED (1987) Absence of
sparing of spatial navigation, skilled forelimb and tongue use and limb
posture in the rat after neonatal dopamine depletion. Physiol Behav 40:
247–253. CrossRef Medline
Wu S, Wu Y, Capecchi MR (2006) Motoneurons and oligodendrocytes are
sequentially generated from neural stem cells but do not appear to share
common lineage-restricted progenitors in vivo. Development 133:581–
590. CrossRef Medline
Zhou QY, Palmiter RD (1995) Dopamine-deficient mice are severely hypo-
active, adipsic, and aphagic. Cell 83:1197–1209. CrossRef Medline
Zhuang X, Masson J, Gingrich JA, Rayport S, Hen R (2005) Targeted gene
expression in dopamine and serotonin neurons of the mouse brain.
J Neurosci Methods 143:27–32. CrossRef Medline
Zigmond MJ, Stricker EM (1973) Recovery of feeding and drinking by rats
after intraventricular 6-hydroxydopamine or lateral hypothalamic le-
sions. Science 182:717–720. CrossRef Medline
Zigmond MJ, Stricker EM (1980) Supersensitivity after intraventricular
6-hydroxydopamine: relation to dopamine depletion. Experientia 36:
436–438. CrossRef Medline
Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM (1984) Neuro-
chemical compensation after nigrostriatal bundle injury in an animal
model of preclinical parkinsonism. Arch Neurol 41:856–861. CrossRef
Medline
Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990)
Compensations after lesions of central dopaminergic neurons: some clin-
ical and basic implications. Trends Neurosci 13:290–296. CrossRef
Medline
Golden et al. • Dopamine-Dependent Compensation J. Neurosci., October 23, 2013 • 33(43):17095–17107 • 17107
